Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Interest & Investment Income (2023 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Interest & Investment Income for 3 consecutive years, with $647000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 37.25% to $647000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 45.63% year-over-year, with the annual reading at $4.6 million for FY2025, 35.99% up from the prior year.
  • Interest & Investment Income hit $647000.0 in Q4 2025 for Vistagen Therapeutics, up from $630000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.5 million in Q4 2023 to a low of $98000.0 in Q2 2023.
  • Historically, Interest & Investment Income has averaged $899636.4 across 3 years, with a median of $855000.0 in 2025.
  • Biggest five-year swings in Interest & Investment Income: soared 1326.53% in 2024 and later crashed 50.51% in 2025.
  • Year by year, Interest & Investment Income stood at $1.5 million in 2023, then crashed by 32.79% to $1.0 million in 2024, then plummeted by 37.25% to $647000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for VTGN at $647000.0 in Q4 2025, $630000.0 in Q3 2025, and $711000.0 in Q2 2025.